Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1954 1
1965 1
1970 1
1975 1
1978 1
1979 1
1981 9
1982 11
1983 13
1984 18
1985 16
1986 7
1987 2
1988 2
1990 1
1991 1
1993 5
1994 1
1995 3
2001 1
2003 1
2004 3
2005 1
2006 1
2007 3
2008 2
2009 5
2010 4
2011 3
2012 4
2013 13
2014 10
2015 11
2016 15
2017 6
2018 6
2019 8
2020 13
2021 18
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

227 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: de jonge av. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Among authors: de jonge av. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
'Watchful attendance' during labour and birth.
de Jonge A, Dahlen H, Downe S. de Jonge A, et al. Sex Reprod Healthc. 2021 Jun;28:100617. doi: 10.1016/j.srhc.2021.100617. Epub 2021 Mar 19. Sex Reprod Healthc. 2021. PMID: 33774268 Free article. No abstract available.
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT, Kochupurakkal B, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI. Do KT, et al. Among authors: de jonge a. Clin Cancer Res. 2021 Sep 1;27(17):4710-4716. doi: 10.1158/1078-0432.CCR-21-1279. Epub 2021 Jun 15. Clin Cancer Res. 2021. PMID: 34131002 Clinical Trial.
Effectiveness of routine third trimester ultrasonography to reduce adverse perinatal outcomes in low risk pregnancy (the IRIS study): nationwide, pragmatic, multicentre, stepped wedge cluster randomised trial.
Henrichs J, Verfaille V, Jellema P, Viester L, Pajkrt E, Wilschut J, van der Horst HE, Franx A, de Jonge A; IRIS study group. Henrichs J, et al. Among authors: de jonge a. BMJ. 2019 Oct 15;367:l5517. doi: 10.1136/bmj.l5517. BMJ. 2019. PMID: 31615781 Free PMC article. Clinical Trial.
227 results